Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

896 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Maertens JA, et al. Among authors: lortholary o. Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10. Lancet. 2016. PMID: 26684607 Clinical Trial.
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Herbrecht R, et al. Among authors: lortholary o. N Engl J Med. 2002 Aug 8;347(6):408-15. doi: 10.1056/NEJMoa020191. N Engl J Med. 2002. PMID: 12167683 Free article. Clinical Trial.
Antifungal therapy of Aspergillus invasive otitis externa: efficacy of voriconazole and review.
Parize P, Chandesris MO, Lanternier F, Poirée S, Viard JP, Bienvenu B, Mimoun M, Méchai F, Mamzer MF, Herman P, Bougnoux ME, Lecuit M, Lortholary O. Parize P, et al. Among authors: lortholary o. Antimicrob Agents Chemother. 2009 Mar;53(3):1048-53. doi: 10.1128/AAC.01220-08. Epub 2008 Dec 22. Antimicrob Agents Chemother. 2009. PMID: 19104029 Free PMC article. Review.
Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults.
Lebeaux D, Lanternier F, Elie C, Suarez F, Buzyn A, Viard JP, Bougnoux ME, Lecuit M, Jullien V, Lortholary O. Lebeaux D, et al. Among authors: lortholary o. Antimicrob Agents Chemother. 2009 Dec;53(12):5224-9. doi: 10.1128/AAC.00939-09. Epub 2009 Sep 14. Antimicrob Agents Chemother. 2009. PMID: 19752284 Free PMC article.
International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole.
Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, Cornet M, Greene J, Herbrecht R, Lacroix C, Grenouillet F, Raad I, Sitbon K, Troke P; French Mycoses Study Group. Lortholary O, et al. Antimicrob Agents Chemother. 2010 Oct;54(10):4446-50. doi: 10.1128/AAC.00286-10. Epub 2010 Jul 12. Antimicrob Agents Chemother. 2010. PMID: 20625156 Free PMC article.
Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome.
Gamaletsou MN, Rammaert B, Bueno MA, Moriyama B, Sipsas NV, Kontoyiannis DP, Roilides E, Zeller V, Prinapori R, Taj-Aldeen SJ, Brause B, Lortholary O, Walsh TJ. Gamaletsou MN, et al. Among authors: lortholary o. J Infect. 2014 May;68(5):478-93. doi: 10.1016/j.jinf.2013.12.008. Epub 2013 Dec 27. J Infect. 2014. PMID: 24378282 Free PMC article. Review.
896 results